Zhongjing Wanxi Pharmaceutical Co., Ltd. Shines at 2025 Henan Healthcare Industry Conference

On March 20, the 2025 Henan High-Quality Development Conference for Medical and Health Industry & Supply Chain Finance Summit, themed “Activating Healthcare, Integrating the Future” was held in Zhengzhou. Experts, scholars, and enterprise representatives from China’s healthcare sector gathered to discuss opportunities and challenges, exchange cutting-edge innovations, and promote collaborative development across the industry chain. Zhangjing Wanxi Pharmaceutical Co., Ltd., a leading unit of Henan Province Biopharmaceutical Industry Alliance, was invited to participate conference, successfully singed agreements, and captivated attendees with its groundbreaking achievements, demonstrating its profound expertise and innovative capabilities in TCM (traditional Chinese medicine).

The conference was guided by Department of Industry and Information Technology of Henan Province, Health Commission of Henan Province, Henan Daily Newspaper Group Co., Ltd., Healthcare Security Administration of Henan Province, and Henan Medical Products Administration. It was co-organized by Henan Daily Newspaper Financial Media Center, Henan Modern Pharmaceutical Industry Alliance, and Zhengzhou Medical Device Association. The event was managed by Dahe Financial Cube, Financial Cube Factoring, and Financial Cube Supply Chain.

The conference further expanded Zhongjing Wanxi Pharmaceutical Co., Ltd.’s market channels, efficiently linked upstream and downstream of the industry chain, effectively bridged the “last mile” between products and market demand, opening up broader development space for the company.

During the corporate introduction session, Zhangjing Wanxi Pharmaceutical Co., Ltd. highlighted Pipa Qingfei Granules—Henan’s first Class 3.1 TCM new drug independently researched and developed by the company. This product is originated from the classic prescription "Pi Pa Qing Fei Yin" in Wu Qian's "Golden Mirror of Medicine" from the Qing Dynasty, and is composed of Radix et Rhizoma Ginseng, Folium Eriobotryae, Radix et Rhizoma Glycyrrhizae, Rhizoma Coptidis, Cortex Mori, and Cortex Phellodendri Chinensis. It demonstrates remarkable in treating Lung-Wind Acne, especially adolescent acne and rosacea, especially adolescent acne, acne, and rosacea, unlike traditional skin medications. Pi Pa Qing Fei Granules focus on systemic regulation, abandon single drug administration, and fundamentally address skin issues caused by lung heat, providing a new and safe treatment option for a wide range of patients. This innovation marks a breakthrough for Zhangjing Wanxi Pharmaceutical Co., Ltd. in TCM R&D and sets a new benchmark for Henan’s pharmaceutical industry.

In the future, Zhongjing Wanxi Pharmaceutical Co., Ltd will continue to increase research and development investment, explore more classic prescriptions, promote the integration of  production and sales, drive the inheritance and innovation of TCM, provide society with more high-quality, safe, and reliable medicines, and contribute Zhongjing’s strength to step up efforts to make Henan a medicine-strong province.

In the future, Zhongjing Wanxi Pharmaceutical Co., Ltd will continue to increase research and development investment, explore more classic prescriptions, promote the integration of  production and sales, drive the inheritance and innovation of TCM, provide society with more high-quality, safe, and reliable medicines, and contribute Zhongjing’s strength to step up efforts to make Henan a medicine-strong province.